These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 26729493)

  • 1. Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.
    Cabot G; Zamorano L; Moyà B; Juan C; Navas A; Blázquez J; Oliver A
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1767-78. PubMed ID: 26729493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.
    Cabot G; López-Causapé C; Ocampo-Sosa AA; Sommer LM; Domínguez MÁ; Zamorano L; Juan C; Tubau F; Rodríguez C; Moyà B; Peña C; Martínez-Martínez L; Plesiat P; Oliver A
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7415-7423. PubMed ID: 27736752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
    Cabot G; Bruchmann S; Mulet X; Zamorano L; Moyà B; Juan C; Haussler S; Oliver A
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3091-9. PubMed ID: 24637685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa.
    Cabot G; Florit-Mendoza L; Sánchez-Diener I; Zamorano L; Oliver A
    J Antimicrob Chemother; 2018 Dec; 73(12):3322-3331. PubMed ID: 30189050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the exoU genotype with a multidrug non-susceptible phenotype and mRNA expressions of resistance genes in Pseudomonas aeruginosa.
    Takata I; Yamagishi Y; Mikamo H
    J Infect Chemother; 2018 Jan; 24(1):45-52. PubMed ID: 29107652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
    Henrichfreise B; Wiegand I; Luhmer-Becker I; Wiedemann B
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B; Zamorano L; Juan C; Pérez JL; Ge Y; Oliver A
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China.
    Zeng ZR; Wang WP; Huang M; Shi LN; Wang Y; Shao HF
    Diagn Microbiol Infect Dis; 2014 Mar; 78(3):268-70. PubMed ID: 24359931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea.
    Lee JY; Ko KS
    Int J Antimicrob Agents; 2012 Aug; 40(2):168-72. PubMed ID: 22633564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of carbapenem resistance mechanisms in clinical isolates of XDR Pseudomonas aeruginosa.
    De Rosa A; Mutters NT; Mastroianni CM; Kaiser SJ; Günther F
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1547-1552. PubMed ID: 31152264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic and genotypic detection of antibiotic resistance of
    Abbas HA; El-Ganiny AM; Kamel HA
    Afr Health Sci; 2018 Mar; 18(1):11-21. PubMed ID: 29977252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa.
    Blázquez J; Gómez-Gómez JM; Oliver A; Juan C; Kapur V; Martín S
    Mol Microbiol; 2006 Oct; 62(1):84-99. PubMed ID: 16956383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
    Moyá B; Beceiro A; Cabot G; Juan C; Zamorano L; Alberti S; Oliver A
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4771-8. PubMed ID: 22733064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates.
    Pasca MR; Dalla Valle C; De Jesus Lopes Ribeiro AL; Buroni S; Papaleo MC; Bazzini S; Udine C; Incandela ML; Daffara S; Fani R; Riccardi G; Marone P
    Microb Drug Resist; 2012 Feb; 18(1):23-32. PubMed ID: 21797666
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Fraile-Ribot PA; Mulet X; Cabot G; Del Barrio-Tofiño E; Juan C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.